Laminin α1 reduces muscular dystrophy in dy2Jmice

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

Standard

Laminin α1 reduces muscular dystrophy in dy2Jmice. / Gawlik, Kinga I.; Harandi, Vahid M.; Cheong, Rachel Y.; Petersén, Åsa; Durbeej, Madeleine.

I: Matrix Biology, Vol. 70, 2018, s. 36-49.

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

Harvard

APA

CBE

MLA

Vancouver

Author

RIS

TY - JOUR

T1 - Laminin α1 reduces muscular dystrophy in dy2Jmice

AU - Gawlik, Kinga I.

AU - Harandi, Vahid M.

AU - Cheong, Rachel Y.

AU - Petersén, Åsa

AU - Durbeej, Madeleine

PY - 2018

Y1 - 2018

N2 - Muscular dystrophies, including laminin α2 chain-deficient muscular dystrophy (LAMA2-CMD), are associated with immense personal, social and economic burdens. Thus, effective treatments are urgently needed. LAMA2-CMD is either a severe, early-onset condition with complete laminin α2 chain-deficiency or a milder, late-onset form with partial laminin α2 chain-deficiency. Mouse models dy 3K /dy 3K and dy 2J /dy 2J , respectively, recapitulate these two forms of LAMA2-CMD very well. We have previously demonstrated that laminin α1 chain significantly reduces muscular dystrophy in laminin α2 chain-deficient dy 3K /dy 3K mice. Among all the different pre-clinical approaches that have been evaluated in mice, laminin α1 chain-mediated therapy has been shown to be one of the most effective lines of attack. However, it has remained unclear if laminin α1 chain-mediated treatment is also applicable for partial laminin α2 chain-deficiency. Hence, we have generated dy 2J /dy 2J mice (that express a substantial amount of an N-terminal truncated laminin α2 chain) overexpressing laminin α1 chain in the neuromuscular system. The laminin α1 chain transgene ameliorated the dystrophic phenotype, restored muscle strength and reduced peripheral neuropathy. Thus, these findings provide additional support for the development of laminin α1 chain-based therapy for LAMA2-CMD.

AB - Muscular dystrophies, including laminin α2 chain-deficient muscular dystrophy (LAMA2-CMD), are associated with immense personal, social and economic burdens. Thus, effective treatments are urgently needed. LAMA2-CMD is either a severe, early-onset condition with complete laminin α2 chain-deficiency or a milder, late-onset form with partial laminin α2 chain-deficiency. Mouse models dy 3K /dy 3K and dy 2J /dy 2J , respectively, recapitulate these two forms of LAMA2-CMD very well. We have previously demonstrated that laminin α1 chain significantly reduces muscular dystrophy in laminin α2 chain-deficient dy 3K /dy 3K mice. Among all the different pre-clinical approaches that have been evaluated in mice, laminin α1 chain-mediated therapy has been shown to be one of the most effective lines of attack. However, it has remained unclear if laminin α1 chain-mediated treatment is also applicable for partial laminin α2 chain-deficiency. Hence, we have generated dy 2J /dy 2J mice (that express a substantial amount of an N-terminal truncated laminin α2 chain) overexpressing laminin α1 chain in the neuromuscular system. The laminin α1 chain transgene ameliorated the dystrophic phenotype, restored muscle strength and reduced peripheral neuropathy. Thus, these findings provide additional support for the development of laminin α1 chain-based therapy for LAMA2-CMD.

KW - Basement membrane

KW - Laminin

KW - Muscular dystrophy

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=85043363212&partnerID=8YFLogxK

U2 - 10.1016/j.matbio.2018.02.024

DO - 10.1016/j.matbio.2018.02.024

M3 - Article

AN - SCOPUS:85043363212

VL - 70

SP - 36

EP - 49

JO - Matrix Biology

JF - Matrix Biology

SN - 1569-1802

ER -